Pfizer fleshing out its model

Since announcing the Biotherapeutics and Bioinnovation Center in October last year, Pfizer Inc. has begun to string together deals it anticipates will provide proof-of-principle for a model it hopes will successfully marry the nimbleness and entrepreneurialism of biotech with the scale and resources of big pharma.

The pharma company believes its approach will create a better partnering interface for academia and biotech startups and help it play catch-up in the biologics space...